Efficacy of three month yoga intervention on the management of type 1 diabetes A randomized controlled trial

Abstract

The chronic autoimmune disease known as type 1 diabetes mellitus (T1DM) is brought on by newlinethe death of the pancreatic and#946; cells that produce insulin, which results in insulin insufficiency newlineand hyperglycemia. Although it can occur at any age, children and adolescents are most likely newlineto experience it. T1DM, which has increased over the past 25 years, affects about 10% of all newlinediabetics globally. In 2021, 8.4 million persons worldwide were forecast to have type 1 diabetes newlinemellitus (T1DM); by 2040, that number is expected to rise to 13.5 17.4 million. The 10th newlineedition of the International Diabetes Federation (IDF) reports that the number of children and newlineadolescents worldwide who have type 1 diabetes is on the rise. The rising prevalence of Type newline1 diabetes will also lead to other comorbidities (Zaharia et al., 2022), which are associated with newlinea socioeconomic burden in developing nations (Andersen et al., 2024), thereby increasing the newlinedemand for complementary therapies, such as yoga, which can help manage T1DM and related newlinecomorbidities. Also, this rising burden of diabetes globally as well as in India, fuelled by newlinelifestyle factors and stress, increases the demand for therapies like yoga, which aids in the newlinereduction of psychological burden (Nagarathna et al, 2020). T1DM patients who follow strict newlineglycaemic control plans are more likely to experience severe hypoglycaemic episodes, which newlineare typified by the requirement for outside help to restore glucose levels. (Gubitosi et al., 2017). newlineIn certain situations, hyperglycemia can cause tissue and organ damage over time. More severe newlinetypes of diabetic ketoacidosis and hyperosmolar can also result in stupor and coma. (Alyahyawi newlineet al, 2021). According to interesting research, yoga therapy also improves pro-inflammatory newlinemarkers such as Interleukin-6 (IL-6) (Raveendran et al, 2018), C Reactive Protein (CRP) newline(Kinser et al, 2012), highly sensitive CRP (hs-CRP) (Saud et al, 2022), and the incretin effect newlinethrough glucagon-like peptide-1 (GLP-1). These findings suppo